Orthoclone OKT3 targets the CD3 molecule that is present exclusively on T cells and depletes them from the circulation, which makes the drug an effective immunomodulator. Unfortunately ...

Our (former) minimoon, known formally as 2020 CD3, was officially identified in February after it had been orbiting our planet for at least a year, astronomers estimate. This happy little surprise ...

When I represented CD3, the first document I read whenever I returned to New York from Washington was a weekly review of our casework. The memo included details of veterans who received ...

a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through Phase 1 clinical development in hematologic cancers. In 2021, Xencor entered a collaboration and license agreement with ...

Rare B-cell neoplasms with plasmablastic differentiation may aberrantly express CD3 by immunohistochemical staining, which places a great challenge for diagnosis. We here studied 17 cases of CD3 ...

SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3 ...

CD3 (including its subunits CD3ε, CD3δ, CD3γ, and CD3ζ) is the central component of the TCR-CD3 complex and is crucial for recognizing T cells and responding to antigens. Every subunit of CD3 ...

Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease. Treatment with the monoclonal antibody ...

Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...